GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.

Corey Hubbafd 11/6/26 Corey Hubbafd 11/6/26

Beyond the Plaque Trap: How Spinal Cord Drugs, Immune Sleep Fixes, and Smart Injections Are Transforming Global Alzheimer’s Care in 2026

Discover the first-week November 2026 Alzheimer's research breakthroughs. Learn how repurposed spinal cord drugs repair DNA, immune cells restore sleep, 5-year CTAD trial data proves longevity, and smart home healthtech supports caregivers.

Corey Hubbafd 10/16/26 Corey Hubbafd 10/16/26

Decoding the Latest Alzheimer's Setback: Why J&J’s "Failed" Drug Trial is Actually a Hidden Victory for Brain Science

When we think about the fight against Alzheimer’s disease, we often picture a coordinated, unstoppable march toward a cure led by massive organizations like the National Institute on Aging and the Alzheimer's Association.

Corey Hubbafd 10/12/26 Corey Hubbafd 10/12/26

Why New Alzheimer’s Treatments are Leaving Atypical Patients Behind

There is a massive blind spot in the current landscape of neurodegenerative care, and it’s one that should keep every health-tech developer awake at night. For decades, the public and medical consciousness has viewed Alzheimer’s disease through a single, narrow lens: the loss of memory. We imagine the grandmother who forgets a name or the father who loses his keys.

Corey Hubbafd 10/3/26 Corey Hubbafd 10/3/26

Finding Inner Peace: Contemplative Meditation for Alzheimer's Caregivers

Caring for a loved one with Alzheimer's disease can be an emotionally and physically exhausting journey. The constant demands, coupled with the heartbreak of witnessing the gradual decline of a once-familiar person, can take a significant toll on caregivers' well-being.

Corey Hubbafd 10/1/26 Corey Hubbafd 10/1/26

The Regulatory Shift: Why Diversity Is Now a Technical Requirement

Discover how Glassbury AI’s agentic NLP platform, SYCQ 1.0, solves the FDA Diversity Action Plan (DAP) mandate and accelerates Phase III Alzheimer’s clinical trial matching.

Corey Hubbard 9/8/26 Corey Hubbard 9/8/26

Beyond Clearing Trash: Blocking the IDOL Enzyme Could Revolutionize Alzheimer's Care

Indiana University researchers have discovered that blocking the IDOL enzyme in neurons doesn't just clear toxic Alzheimer's plaques—it also lowers genetic risk (APOE4) and builds cognitive resilience. Read on to learn how this discovery could pave the way for a revolutionary new pill.